血友病患者丙型肝炎病毒清除后肝病残留负担:基因治疗时代的警示
该前瞻性肝病筛查研究纳入119例既往丙型肝炎病毒(HCV)感染的血友病患者,评估HCV清除后晚期纤维化/肝硬化的残留负担。96例(81%)存在至少1项慢性肝损伤潜在危险因素,21例(18%)提示晚期纤维化/肝硬化,10例(8%)有食管静脉曲张,3例(3%)有肝细胞癌。57例前瞻性分析中HCV清除后肝脏硬度测量(LSM)和无创检测(NITs)下降(P < .05),但肝硬化特异性超声征象不变;80例LSM <10 KPa者中23例(29%)有至少1项提示晚期纤维化/肝硬化的超声征象,LSM <8 KPa者中类似比例为18%。
要点
- HCV清除后81%(96/119)的血友病患者仍存在至少1项慢性肝损伤潜在危险因素。
- 18%(21/119)临床、生化、肝脏形态和/或LSM提示晚期纤维化/肝硬化,8%有食管静脉曲张,3%有肝细胞癌。
- HCV清除后LSM和NITs下降(P < .05),但肝硬化特异性超声征象不变,可能不足以排除晚期纤维化/肝硬化。
核心结论
- HCV清除后慢性肝损伤危险因素常见,但LSM和NITs的变化可能不足以准确排除晚期纤维化/肝硬化,基因治疗时代需专门诊断性检查评估血友病患者肝脏健康。
研究设计与样本
- 前瞻性肝病筛查研究,纳入119例既往HCV感染的血友病患者(中位年龄53岁,范围36-87岁;血友病A 108例,血友病B 11例)。
- 对其中57例患者前瞻性进行HCV清除前后LSM、超声和纤维化NITs分析。
主要发现
- 96例(81%)存在至少1项慢性肝损伤潜在危险因素,代谢危险因素最常见,51例(44%)超声有脂肪变性。
- 21例(18%)临床、生化、肝脏形态和/或LSM提示晚期纤维化/肝硬化;10例(8%)有食管静脉曲张,3例(3%)有肝细胞癌。
- 57例前瞻性分析中,HCV清除后LSM和NITs下降(P < .05),但肝硬化特异性超声征象保持不变。
- 80例LSM <10 KPa患者中23例(29%)有至少1项提示晚期纤维化/肝硬化的超声征象;LSM <8 KPa患者中类似比例为18%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruling out advanced fibrosis/cirrhosis is mandatory for persons with hemophilia (PWH) who are candidates for gene therapy. However, clinical evaluation and noninvasive tests (NITs) may be inaccurate after hepatitis C virus (HCV) clearance. We conducted a prospective hepatological screening to detect advanced fibrosis/cirrhosis in PWH after HCV clearance. Any risk factor of chronic liver damage was registered by using biochemical data, liver stiffness measurement (LSM), and ultrasound (US). A pre/post-HCV clearance analysis was conducted prospectively in a subgroup of patients who underwent LSM, US, and NITs for fibrosis. We evaluated 119 patients (median age, 53 years; range, 36-87 years) with a previous HCV infection (hemophilia A, n = 108; hemophilia B, n = 11). Ninety-six (81%) presented at least 1 potential risk factor of chronic liver damage. Metabolic risk factors were the most prevalent, with 51 patients (44%) having US steatosis. In 21 patients (18%), clinical, biochemical, liver morphology, and/or LSM were suggestive of advanced fibrosis/cirrhosis. Furthermore, 10 patients (8%) had esophageal varices and 3 (3%) had hepatocellular carcinoma. In 57 patients included in the prospective analysis, LSM and NITs were reduced after HCV clearance (P < .05), but US signs specific of cirrhosis remained unchanged. Overall, 23 of 80 patients (29%) with LSM <10 KPa had at least 1 US sign suggestive of advanced fibrosis/cirrhosis. A similar proportion (18%) was observed for LSM <8 KPa. Overall, risk factors of chronic liver damage are frequent after HCV clearance, but changes in LSM and NITs after clearance may be inaccurate to rule out advanced fibrosis/cirrhosis. A specific diagnostic workup is warranted to evaluate liver health in PWH in the era of gene therapy.
引用
- La Mura V, Bitto N, Capelli C, et al. Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy. Blood Adv. 2023. PMID: 37505111. doi:10.1182/bloodadvances.2023010723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。